Anti-tubercular peptides: A quest of future therapeutic weapon to combat tuberculosis  by Khusro, Ameer et al.
HOSTED BY Contents lists available at ScienceDirect
Asian Paciﬁc Journal of Tropical Medicine 2016; 9(11): 1023–1034 1023Asian Paciﬁc Journal of Tropical Medicine
journal homepage: http://ees.elsevier.com/apjtmReview http://dx.doi.org/10.1016/j.apjtm.2016.09.005First author: Ameer Khusro, Research Department of Plant Biology and




✉Corresponding author: Paul Agastian, Research Department of Plant Biology




Peer review under responsibility of Hainan Medical University.
Foundation Project: This study was supported by Maulana Azad National
Fellowship (F1-17.1/ 2015-16/MANF-2015-17-BIH-60730), University Grants
Commission, Delhi, India.
1995-7645/Copyright © 2016 Hainan Medical University. Production and hosting by Elsevier B.V. This is an open access articl
creativecommons.org/licenses/by-nc-nd/4.0/).Anti-tubercular peptides: A quest of future therapeutic weapon to combat tuberculosisAmeer Khusro, Chirom Aarti, Paul Agastian✉Research Department of Plant Biology and Biotechnology, Loyola College, Nungambakkam, Chennai 600034, Tamil Nadu, IndiaARTICLE INFO
Article history:
Received 5 Jul 2016
Received in revised form10 Sep 2016
Accepted 20 Sep 2016






Tuberculosis (TB) is a symbolic menace to mankind, infecting almost one third of the
world's populace and causing over a million mortalities annually. Mycobacterium
tuberculosis (Mtb) is the key pathogen of TB that invades and replicates inside the host's
macrophage. With the emerging dilemma of multi-drug resistant tuberculosis (MDR-TB)
and extensively-drug resistant tuberculosis (XDR-TB), the exigency for developing new
TB drugs is an obligation now for worldwide researchers. Among the propitious anti-
mycobacterial agents examined in last few decades, anti-tubercular peptides have been
substantiated to be persuasive with multiple advantages such as low immunogenicity,
selective afﬁnity to bacterial negatively charged cell envelopes and most importantly
divergent mechanisms of action. In this review, we epitomized the current advances in the
anti-tubercular peptides, focusing the sources and highlighting the mycobactericidal
mechanisms of promising peptides. The review investigates the current anti-tubercular
peptides exploited not only from human immune cells, human non-immune cells, bac-
teria and fungi but also from venoms, cyanobacteria, bacteriophages and several other
unplumbed sources. The anti-tubercular peptides of those origins are also known to have
unique second non-membrane targets within Mtb. The present context also describes the
several cases that manifested the severe side effects of extant anti-TB drugs. The
downfall, failure to reach clinical trial phases, inept to MDR- or XDR-TB and severe
complications of the currently available anti-tubercular drugs accentuate the imperative
necessity to develop efﬁcacious drugs from adequate anti-tubercular peptides. Keeping in
view of the emerging trends of drug resistant Mtb globally and unexampled myco-
bactericidal characteristics of peptides, the anti-tubercular peptides of varied origins can
be used as a potential weapon to eradicate TB in future by developing new therapeutic
drugs.1. Introduction
Bacterial infections are signiﬁcant threats globally, causing
over a million deaths every year. Tuberculosis (TB) is one of themost serious tropical diseases, caused by Mycobacterium tuber-
culosis (Mtb). TB is a severe airborne fatal disease which infects
one third of the world's population. TB is a global pulmonary
health problem and is more common among men than women.
TB infects all age groups, mostly affects adults. According to the
World Health Organization (WHO) survey, there were 8.6
million new active cases of TB and 1.3 million deaths during
2012 [1]. There were approximately 9.6 million cases of active
TB estimated in 2014 which culminated in 1.5 million deaths.
Indeed, TB is an endemic disease in the developing countries
and the majority of active TB cases were in the South-East Asia
(29%), followed by African (27%) and Western Paciﬁc (19%)
regions. More than 95% of deaths occurred in developing
countries and India alone accounts for 26% of total TB cases. In
the mid-1990s, the WHO developed the DOTS (direct observed
therapy strategy) to control TB. This strategy was adopted bye under the CC BY-NC-ND license (http://
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therapy treatment by administering crucial ﬁrst-line drugs
(isoniazid, rifampicin, ethambutol and pyrazinamide), followed
by treatment with isoniazid and rifampicin for a period of 4
months. The emergence of multi-drug resistant (MDR) Mtb and
disease recrudesces were one of the consequences of this strat-
egy. Surprisingly, among the newly infected cases of TB,
approximately 13% were co-infected with human immunodeﬁ-
ciency virus (HIV) due to the impairment of the immune system
of the patient, leading to the delayed diagnosis and treatment of
TB [2]. This is because HIV infected persons are compromised
with their immune systems.
Mtb is a weak Gram-positive bacterium that affects human
macrophages, leading to TB. Mtb is aerobic and rod-shaped non-
motile bacillus. The bacterium divides with extremely slow rate
with a generation time of 16–20 h. The high lipid content on the
outer membrane of this bacterium provides its unique charac-
teristics and stained with Ziehl–Neelsen stain (acid-fast stain)
during its microscopic observation. TB causing mycobacteria
viz. Mycobacterium bovis (M. bovis), Mycobacterium africanum
(M. africanum), Mycobacterium canetti (M. canetti) and Myco-
bacterium microti (M. microti) belong to M. tuberculosis com-
plex (MTBC). Among them, M. bovis and M. africanum are not
widespread at present. On the other hand M. canetti and
M. microti are rare, limited to Africa only.
In spite of the discovery of streptomycin and ﬁrst-line anti-
TB drugs, TB continued to ravage the under-developed and
developing countries. The rate of TB development rose once
again with the onset of HIV infections, leading to the utilization
of several drugs towards its cure and addressed the dominant
cause of the emergence of MDR mycobacterium strains. In the
current scenario, there is an emergence of multi-drug resistant
MDR strains, threatening global TB control. MDR-TB is a form
of TB that is resistant to ﬁrst-line anti-TB drugs, at least to
isoniazid (INH) and rifampicin (RIF). The rise of MDR-TB led
to the use of second-line drugs (para-aminosalicylic acid,Figure 1. Pathogenicity of Mtb and utilization of macrophage, where I – maccycloserine, terizidone, ethionamide, prothionamide, thio-
acetazone, linezolid, levoﬂoxacin, moxiﬂoxacin, oﬂoxacin,
gatiﬂoxacin and capreomycin) that are very expensive, toxic and
require long term treatment, causing the poor patient compli-
ance. In 2014, 480 thousand cases were reported globally
developing MDR-TB, with mortality counts of 123 thousand.
XDR-TB is a subset of MDR-TB which is resistant to the
second-line anti-TB drugs, ﬂuoroquinolones, and one of the three
injectable anti-TB agents (e.g. amikacin, kanamycin and cap-
reomycin). Currently, the cases of MDR-TB and XDR-TB are
continuously emerging and few countries reported at least one
case of XDR-TB, which represented 9.6% of all MDR-TB cases.
2. Mtb pathogenicity
The intracellular pathogen, Mtb primarily infects human
pulmonary macrophage. Macrophages are specialized cells of
the immune system that engulf and remove the invading mi-
croorganisms through phagocytosis process. In general, during
this process microorganisms are trapped into the phagosomes
which fuse with lysosome and forms phagolysosome. Eventu-
ally, the digestive process occurring inside the phagolysosomes
results into the destruction of invaded microorganisms. How-
ever, Mtb after phagocytised escapes from this defence mecha-
nism by infecting macrophages and survive within the adverse
environment. Mtb utilizes macrophages for its own replication
process (Figure 1). The defence property of Mtb relies on several
survival strategies. Unlike non-pathogenic mycobacterium
strains, ﬁrst of all the pathogenic Mtb arrests the maturation
process of phagosomes and prevents the acidiﬁcation of phag-
osomal compartments. It also inhibits the formation of the ly-
sosomes and phagosomes complex. Further, the bacterium
impairs the apoptosis of macrophage and suppresses the anti-
microbial responses, thus helping the bacterium to escape from
the phagosomes. The bacterium becomes undetectable to innate
immune system because MHC class II antigen avoids itsrophage, II – leucocytes, III – granuloma and IV – Mtb.
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survive in the adverse environment of pulmonary or any other
parts of the host macrophages.
Extensive reports have demonstrated that in spite of the
digestive property of macrophages, Mtb has developed multiple
adaptive strategies to destruct the phagosomal pathways and
survive intracellularly in the host macrophages [3]. The cell
envelop of Mtb constituting diverse lipid contents is a major
factor towards its virulent property. The lipids such as
Sulfated glycolipid (SL), Trehalose dimycolates (TDM),
Dimycocerosate phthiocerol (DIM), Lipoarabinomannan
(LAM), Mannose capped lipoarabinomannan (Man-LAM) and
Phosphatidylinositol mannoside (PIM) present in the cell
envelop contributes to the virulence of the bacterium.
Lipoarabinomannan (LAM) and phosphatidylinositol
mannoside (PIM) have the capability to interfere with the host
phagosome pathway [4]. LAM and PIM arrest phagosome
fusion and acidiﬁcation [5]. On the other hand, SL and TDM
prevent the fusion of lysosome [6]. However, the formation of
permeability barrier by cell envelops and inhibition of
acidiﬁcation is carried out by DIM [7].
According to the report of Kusner and Barton [8], the virulent
Mtb restricts CR-mediated Ca2+ signaling during phagocytosis
process and arrests the acidiﬁcation and fusion mechanism. Man-
LAM may incorporate with Mtb-containing phagosomes mem-
brane and blocks the macrophage sphingosine kinase (SK) or
Ca2+/calmodulin phosphatidylinositol (PI)3 kinase hVPS34
cascade and PIP3 (phosphatidylinositol 3,4,5-trisphosphate)
production, resulting the inactivation of early endosome antigen 1
(EEA1), a major component in phagosome maturation mecha-
nism [9]. LAM may also impair the host phagosome maturation
process by activating p38 mitogen-activated protein kinase (p38
MAPK), which are responsible for the down-regulation of EEA1
recruitment mechanism [5]. PIM has the capability to avoid
phagosomal acidiﬁcation by stimulating the fusion of Mtb-
containing phagosome with early endosome compartments. It
facilitates the access to nutrients necessary for the pathogen's
survival strategy. The depletion of these essential nutrients results
into the inactivation of Mtb inside macrophages [7].
TACO (tryptophan aspartate coat protein) is a host protein,
residing on the live and virulent Mtb containing phagosomes.
Unlike the uncoated phagosomes, TACO-coated Mtb-containing
phagosomes will not be presented to lysosomes for degradation
process and thus inhibits the fusion of the phagosome [10]. Mtb
arrests apoptosis of the infected cells at the preliminary stage and
induces necrosis-like cell death to escape from the hosts [11].
Recently, a TACO binding protein called as mycobacterial
Lipoamide dehydrogenase C (LpdC) has been studied to induce
the virulence characteristics of Mtb. The protein supports Mtb to
avoid the toxicity of host's reactive oxygen species (ROS) by
forming a constituent of peroxynitrite reductase/peroxidase [4].
The pathogenicity mechanism and virulence characteristics of
Mtb explained above clearly show that Mtb has developed
survival strategies to evade phagocytosis process.
The current scenario of anti-tubercular therapies has drawn
attention to achieve competent and durable treatment of the
emerging problems of TB. In the last few years, the naturally
occurring compounds and their derivatives due to vast biological
properties have been taken into account for the investigation and
development of new potent drug candidates. Among the natu-
rally occurring molecules, antimicrobial peptides (AMPs) have
been found to be more effective with invading potential due totheir unique molecular features and multiple mode of action.
These peptides are known to bind with a broad range of bio-
logical targets and show both antimycobacterial as well as
immunomodulatory properties.3. Anti-tubercular peptides as new alternative
mycobactericidal agents
Although several alternate strategies have ensued in the last
few decades in order to combat TB, anti-tubercular peptides
remain to be the leading alternative due to their versatility nature
by virtue of several mechanism and immunomodulation prop-
erties. In fact, anti-tubercular peptides are the antimicrobial
peptides showing plausible activity against Mtb. These are the
naturally synthesized endogenous oligopeptides constituting
varying number of amino acids.
The active anti-tubercular peptides as TB therapeutics are
discussed below:4. Human immune cells associated anti-tubercular
peptides
4.1. Cathelicidins
Cathelicidins are one of the most crucial human immune cells
derived small cationic AMPs that play a considerable role in
anti-tubercular activities. Cathelicidins belong to the host de-
fense peptide that has a remarkable impact on the elimination of
pathogens. Neutrophil granules store during prepropeptides
stage of cathelicidins. These are the bipartite molecules and their
mycobactericidal properties are due to the conserved N-terminal
cathelin domain and a variable C-terminal domain (Figure 2a).
However, the N-terminal cathelin domain is responsible for the
intracellular storage part of cathelicidins. Cathelicidins confer
the inducible expression in various cells and tissues which is
regulated by several stimuli [12]. The activated neutrophils and
epithelial cells are responsible for the synthesis of human
cathelicidins antimicrobial peptides (hCAP18), then secreted
into extracellular milieu. Proteinase-3 cleaves hCAP18 to form
LL-37 peptide. Basically, LL-37 is the C-terminal of hCAP18
and taken up by neutrophils. The cathelicidins are induced by
several stimuli, which then show anti-tubercular activity.
The intracellular survival of Mtb is inhibited by the exoge-
nous addition of LL-37 or endogenous over-expression of LL-37
in macrophages. According to Sonawane et al. [13], LL-37
exhibited antimycobacterial property in vitro as well as inside
macrophages. LL-37 also contributes in the innate immune
response against Mtb through the activation of G protein-
coupled receptor N-formylpeptide receptor-like-1 (FPRL-1)
[14]. LL-37 acts upon Mtb in vitro by creating pores or the
disruption of cell membrane. On the other hand during in vivo
study, LL-37 involves in Toll-like receptor (TLR) activation of
monocytes to induce the inactivation of Mtb.
Previous reports manifestated that the synthetic peptide LL-
37 had broad spectrum anti-tubercular activity in the epithelial
cells of the lung and in bronchoalveolar lavage ﬂuids. Addi-
tionally, LL-37 contributes in the inhibition of intracellular
mycobacterium through NADPH oxidase 2-dependent process
[15]. Similarly, LL-37 played an efﬁcient role in the induction
and maturation of autophagy pathways induced by vitamin D3
in human monocytes and regulated the transcriptional
Figure 2. PDB structure of human immune cells associated anti-tubercular peptides.
(A) Cathelicidins, (B) a-defensins, (C) b-defensins, (D) q-defensins and (E) granulysin.
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atg-5 via C/EBP-b and MAPK (mitogen-activated protein ki-
nase) activation [16]. The data clearly indicate that cathelicidins
exert anti-tubercular properties as well as immunomodulatory
potential of autophagy regulation during Mtb infection.4.2. Defensins
Defensins are another human immune cell derived anti-
tubercular peptides containing 29–35 amino acid residues and
six highly conserved invariant cysteine residues. The defensins
are major components of the innate immune response against
Mtb, through an oxygen-independent mechanism [17]. Defensins
show non-speciﬁc cytotoxicity to microorganisms. It constitutes
a large portion of the pulmonary innate host defense system
including respiratory epithelia and acts as signaling molecules
for invading pathogens [18]. The precursors of defensins contain
b-sheet-rich fold and six disulﬁde-linked cysteines. a-, b-, and
q-defensins (Figure 2B–D) are the sub-families of defensins
based upon the structural differences. The gene expression study
using microarray divulged that the effecter molecules of a-
defensin were found to be upregulated in patients infected with
TB [19]. During in vivo study, it was observed that b-defensins
along with L-isoleucine showed enhanced anti-tubercular efﬁ-
ciency [20].
The human b-defensins HBD-1 and HBD-2 are principally
expressed at epithelial region and generally both have bacteri-
cidal property. HBD-2 can be transferred to mycobacterium-
containing macrophage phagosomes during the infection and
exert anti-tubercular activity. Currently, the role of HBD4 in the
innate immune defense against mycobacteria has been studied.
The up-regulation of HBD4 expression was observed in the
presence of TLR2/1-mediated IL-1b [21].
Human neutrophil peptide 1 (HNP-1), a type of a-defensins
found in the azurophilic granules of polymorphonuclear neu-
trophils showed signiﬁcant activity against Mtb strain in a
concentration dependent manner with higher MIC (minimum
inhibitory concentration) value than that of ﬁrst-line anti-TB
drugs. The microscopic observation showed that HNP-1 affectedMtb strain by permeabilization of cell membrane and forming
pores [22].
4.3. Granulysin
Granulysin is a cationic glycoprotein that belongs to saposin-
like protein family. It has close resemblance to NK-lysin, con-
sisting of four helical bundle motifs, with the helices enriched
with arginine and lysine residues (Figure 2E). The granulysin
(15 kDa) can invade Mtb by entering into the human macro-
phages. Similarly, recombinant granulysin (15 kDa) were also
known to kill Mtb by aerosol challenge and provided defense
against TB [23]. Granulysins show anti-tubercular activity by
acting upon mycobacterial membranes, leading to the disruption
of synthetic liposomes and induction of apoptosis. However, the
bacterial lysis is unaffected by the reduction of the disulﬁde
bonds present in the peptides.
5. Human non-immune cells associated anti-
tubercular peptides
Human non-immune cells such as hepatocytes, keratinocytes
and eosinophils can also exert anti-tubercular activities through
direct killing mechanisms by producing effective peptides.
These peptides do not induce immunomodulatory activities.
Some of the human non-immune cells associated anti-tubercular
peptides are listed below:
5.1. Hepcidins
Hepcidin is a cationic amphipathic non-immune cells peptide
produced in the liver. It is a key component of iron recycling by
blocking iron absorption in response to iron overload and other
stimuli. The production of hepcidin is markedly induced during
the infection or any inﬂammatory conditions. Iron is essential for
the survival of mycobacteria. Hepcidin mainly works by the
regulation of transmembrane iron transport through binding with
an iron exporter expressed in hepatocytes and macrophages,
called as ferroportin [24]. Both the macrophage and the
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there is secretion of hepcidin by macrophage that restricts the
growth of mycobacteria though blocking the release of the
recycled iron from macrophages. It results into the subsequent
reduction in the extracellular iron concentrations, thereby
makes less available for microorganisms [24]. Thus, Mtb
infections cause the expression of hepcidins in the macrophage
and possess growth inhibition of the bacterial cell. Hepcidin
could inhibit the growth of bacteria by damaging the structure
of the mycobacteria. In general, the stimulation of
macrophages synergistically with mycobacteria and Interferon-
g induced hepcidin mRNA and protein [25].
5.2. HCL2
HCL2 is another non-immune cells derived anti-tubercular
peptide which is part of a seven-bundle helix of the human
cytochrome c oxidase subunit3 (COX3) proteins. Its helical
structure shows close resemblance with early secreted antigenic
target (ESAT-6) protein. ESAT-6 and culture ﬁltrate protein
10 kDa (CFP10) proteins play critical roles in mycobacterial
pathogenesis [26]. HCL2 could disrupt the heterodimeric
interaction between ESAT-6 and CFP10 i.e. ESAT-6: CFP10
complex and affected the survival of Mtb signiﬁcantly by dis-
integrating the cell wall and inhibiting the intracellular as well as
extracellular bacterial growth.
5.3. Ubiquitin-derived peptide
Proteasomes are protein complexes inside eukaryotes and
bacteria that have the ability to degrade damaged or unneeded
proteins by a process called as proteolysis. Proteases favor this
catalytic reaction. Peptides of shorter amino acids are obtained
after the degradation process which is further used in synthe-
sizing new proteins. Proteins are tagged with a small protein
called as ubiquitin, catalyzed by ubiquitin ligases. The prime
function of the proteasome is to degrade proteins. The protea-
some is essential for the pathogenicity of Mtb and therefore the
Mtb proteasome are potential targets. Ubiquitin (Ub) is one of
the post-translational modiﬁcation proteins and usually acts as a
signal for proteasome degradation. Ubiquitin-derived peptides
residing inside the lysosome contribute to the growth inhibition
of Mtb [27]. Autophagy contributes a paramount role for the anti-
tubercular potential of ubiquitin-peptides, because it induces the
fusion of lysosome and Mtb-containing phagosome, enhancing
the delivery of ubiquitin to lysosome [28].
Ub2 is an ubiquitin-derived peptide located in lysosome,
exerting signiﬁcant anti-tubercular activity. The mycobacter-
icidal activity is due to the secondary structure b-sheet of Ub2
that targets the bacterial membrane [29]. However, the sub-
cellular localization studies demonstrated that Ub2 acts both
on the bacterial membrane as well as the cytoplasm. The
incorporation of Ub2 with bacterial membrane causes the
membrane permeability and its exposure to adverse
environments.
In another study the UbGR-ESAT-6 fusion DNA vaccine
inoculation improved antigen-speciﬁc cellular immune re-
sponses, which can be useful against mycobacterial infection.
BALB/c (bagg albino) mice were vaccinated with plasmid
DNA encoding ESAT-6 protein, ubiquitin-fused ESAT-6 DNA
vaccine (UbGR-ESAT-6), pcDNA3-ubiquitin and blankvector. The result demonstrated that Thl-polarized immune
response was induced by ESAT-6 DNA vaccine immunization.
There was enhancement in the production of Thl-type cytokine
(IFN-gamma) and proliferative T-cell responses in mice
immunized with UbGR-ESAT-6 fusion DNA vaccine,
compared to non-fusion DNA vaccine. The relative ratio of
IgG (2a) to IgG (l) and the cytotoxicity of T-cells were also
found to be increased [30].
6. Bacteria associated anti-tubercular peptides
Bacteriocins are ribosomally-synthesized microbicidal pep-
tides produced by Gram-positive or Gram-negative bacteria. In
the case of Gram-negative bacteria, most of the bacteriocins
have been studied and characterized from Escherichia coli
(E. coli) and other enterobacteria, and they are often divided into
microcins (small peptides) or colicins (larger proteins). The
lantibiotics (class I) and the non-lantibiotics (class II) are two
major classes of bacteriocins obtained from Gram-positive
bacteria. The lantibiotics are heat stable peptides constituting
19–38 amino acids with post-translational modiﬁcations
including thioether-based ring structures (known as lanthionine
or b-methyllanthionine). Nisin, subtilin, lacticin 3147 and thur-
icin CD are members of lantibiotics. The class II bacteriocins are
cationic heat stable peptides constituting 25–60 amino acids.
Lactic acid bacteria (LAB) are major producers of class II bac-
teriocins. Class III bacteriocins are less exploited large and heat-
labile protein.
The present necessity for the treatment of TB with novel
target molecules has led to investigate the structural and func-
tional analysis of bioactive peptides. To date, several bacterio-
cins have been studied with different structures and mechanisms.
Few of the potential bacteriocins with anti-tubercular activities
have been listed below:
6.1. Nisin
Nisin is the most characterized polycyclic antimicrobial
protein produced by Lactococcus lactis (L. lactis) subsp. lactis.
It represents the group I lantibiotics and consists of 34 amino
acid residues, including the uncommon amino acids, viz.
dehydroalanin, dehydrobutyrine and lanthionin. Nisin is the
prototypical lantibiotic, ratiﬁed by the US Food and Drug
Administration (FDA) for its application as safe food additives.
Moreover, it inhibits the synthesis of cell wall as well as creates
pores in the bacterial cell membrane (CM) by binding to the
peptidoglycan precursor, lipid II (Figure 3).
Nisin exhibited the growth inhibition of Mycobacterium
smegmatis (a non-pathogenic species of mycobacteria closely
related to Mtb) and M. bovis-Bacillus Calmette Guerin (BCG), a
vaccine strain of pathogenic M. bovis. The study demonstrated
that 2.5 mg/mL of nisin was required to inhibit M. bovis-BCG.
The peptide exhibited a concentration dependent decrease in
internal ATP levels in M. bovis-BCG. In like manner, nisin
reduced both the constituents of proton motive force in myco-
bacterium in a time and concentration dependent manner,
establishing the growth inhibitory mechanism of nisin against
mycobacteria, similar to foodborne pathogens. The hydrolysis
and loss of intracellular ions resulted into the collapse of proton
motive force and low intracellular ATP levels that would
contribute to the antimycobacterial activity of nisin [31].
Figure 3. Bactericidal mechanism of nisin, where I – nisin, II – pore formation, III – lipid II.
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bioengineered hinge derivatives such as nisin S, nisin T and
nisin V displayed greater anti-tubercular activity against Mtb
H37Ra using microtitre alamar blue assay (MABA). Among the
derivatives investigated, Nisin S was found to be the most potent
variant with anti-tubercular property, claiming the ﬁrst report to
illustrate an enhancement of efﬁcacy by bioengineered bacte-
riocin against mycobacteria.
6.2. Lacticin 3147
Lacticin 3147 is another extensively characterized antimi-
crobial peptides that differs from nisin by virtue of requiring two
peptides for optimal activity. Similar to nisin, Lacticin 3147
inhibits the synthesis of cell wall as well as creates pores in the
bacterial cell membrane by binding to the peptidoglycan pre-
cursor, lipid II but distinguished from nisin both genetically as
well as biologically. Lacticin 3147 is a critical bacteriocin pro-
duced by L. lactis subsp. lactis which is temperature and pH
stable. In fact, it is a two-peptide (LtnA1 and LtnA2) lantibiotic
at 1:1 ratio and effective at very low concentrations. Lacticin
3147 obtained from L. lactis showed growth inhibitory activity
against Mtb H37Ra with MIC90 values of 7.5 mg/mL [33].
Dehydroascorbate (dha) reductase plays a major role in the
conversion of L-alanine to D-alanine in lacticin 3147 and its
inhibitory property is due to three D-alanines present in it [34].
The potential to create D-residues in this peptide may
contribute in designing D-amino acid-containing peptides with
anti-tubercular properties.
6.3. E50-52 and Lassomycin
E50-52, obtained from Enterococcus faecalis represents class
IIa bacteriocins. The growth of mycobacterium was inhibited byE50–52 within macrophages at a non-cytotoxic concentration of
0.1 mg/L. In macrophages, the inhibition of mycobacterial
growth was due to E50–liposome complex without affecting the
macrophages membrane. During animal model study, E50–
liposome was injected every 24 h for 5 consecutive days in the
mouse which showed signiﬁcantly increased life span of the
infected mouse, indicating E50 as an adequate peptide in the
treatment of MDR-TB [35].
Lassomycin is a cyclic peptide obtained from Lentzea ken-
tuckyensis. In general, it targets ClpC1P1P2, which is an
essential ATP-dependent protease responsible for the viability of
mycobacteria [36]. Lassomycin binds to an acidic N-terminal
pocket of ClpC1P1P2 and activates its ATPase activity,
leading to uncoupling it from ClpP1P2 proteolysis. The
uncoupling ATPase from proteolytic activity accounts for the
mycobacterium growth inhibition property of lassomycin.
Lassomycin is a unique AMPs because it activates the target
enzyme rather than inhibiting it. Lassomycin showed anti-
tubercular activity with an MIC of 0.8–3 mg/mL against
MDR-TB and XDR-TB isolates [36], representing lassomycin as
a promising anti-TB peptide.
6.4. Other bacteriocins and peptides
The capacity of bacteriocins to inhibit growth of Mtb had
been investigated in limited reports. Sosunov et al. [35] puriﬁed
ﬁve different bacteriocins with antimycobacterial property
which was assessed further using different models including
in vitro mycobacterial cultures, in vitro infection of mouse
macrophages and in vivo high-dose infection of inbred mice.
Similarly, Lactobacillus plantarum and its bacteriocin (plantar-
icin 42) were successfully encapsulated in nano-ﬁbers. The
method may be incorporated for the successful delivery of bac-
teriocins to the speciﬁc sites of mycobacterium infections [37].
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B, isolated from Rhodococcus sp. K01-B0171 were found to be
active against Mtb. The peptides consist of 18 and 20 L-amino
acid residues with an internal linkage between the g-carboxyl
group and a-amino group of Glu8 and Gly1 respectively.
Furthermore, the report demonstrated that the target molecule of
lariatins might abide inside the biosynthetic steps of mycobac-
terial cell wall [38].
Aerococcus sp. ZI1 revealed its potentiality to inhibit the
growth of Mycobacterium smegmatis used as a model to test the
effect on Mtb. The reports demonstrated that Aerococcus sp. ZI1
produces proteinaceous inhibitory substances which should be
puriﬁed and identiﬁed [39]. In the line of previous study, Hassi
et al. [40] and Guendouzi et al. [41] reported Brevibacillus
laterosporus and Bacillus sp. exhibiting antimycobacterial
activity due to the production of proteinaceous substance
respectively.
Nocardithiocin, a novel thiopeptide compound produced by
Nocardia pseudobrasiliensis strain IFM 0757 showed a strong
activity against rifampicin-resistant as well as sensitive Mtb
strains with an MIC of 0.025 mg/mL. The study suggested that
the Nocardia strains are potential sources of antimycobacterial
compounds due to the production of a unique antibiotic,
nocardithiocin [42].
In the line of TB therapy, a series of novel sansanmycin
derivatives were designed, synthesized and appraised for their
growth inhibitory potential against Mtb strain H37Rv with
sansanmycin A (SSA) being the dominant. Among these analogs
investigated, the potent compound exhibited an improved anti-
tubercular activity with an MIC value of 8 mg/mL in compari-
son with SSA, suggesting the further exploration of these ana-
logs for TB treatment [43]. In fact, sansanmycins belong to
nucleosidyl-peptide antibiotics, produced by Streptomyces sp.
Additionally, sansanmycin F and G were also assessed for
their inhibitory activity against Mtb H37Rv, based upon the
alamar blue microplate assay, with signiﬁcant MIC value of
16 mg/mL [44].
7. Fungi derived anti-tubercular peptides
Apart from bacteria, fungi are also potential sources of novel
bioactive compounds or peptides. A large pool of peptides is
secreted by fungi but only few of them being bioactive, espe-
cially as anti-tubercular peptides. Large-scale production of
these bioactive fungal peptides may prove their biotechnological
potential for the growth inhibition of Mtb and may establish
their signiﬁcant role as a valuable, although relatively unex-
plored source of TB therapy.
7.1. Calpinactam
Calpinactam (molecular formula – C38H57N9O8) is an anti-
mycobacterial hexapeptide with a caprolactam ring at its C-ter-
minal, originally isolated from the fungus Mortierella alpina.
Koyama et al. [45] reported the isolation of calpinactam from the
culture broth of Mortierella alpine FKI-4905 by solvent
extraction method, octadecyl silane column chromatography and
preparative HPLC. Calpinactam was found to be active against
Mtb with an MIC value of 12.5 mg/mL. The calpinactam might
be responsible to inhibit the mycobacterial growth by inter-
rupting the biosynthetic steps of cell wall. However, themechanisms of action of calpinactam against Mtb are yet to be
investigated in depth.
7.2. Trichoderin
Pruksakorn et al. [46] isolated three new aminolipopeptides,
namely trichoderins A, A1 and B from marine sponge-derived
fungus of Trichoderma sp. These peptides exhibited their anti-
mycobacterial activity against active and dormant bacilli, Mtb
H37Rv under both aerobic growth conditions and dormancy-
inducing hypoxic conditions, with MIC values ranging from
0.02 to 2.0 mg/mL. The anti-tubercular peptide inhibited the
bacterial growth by impeding the mode of ATP synthesis.
7.3. Bisdethiobis(methylsulfanyl)apoaranotin and
Cordycommunin
Bisdethiobis(methylsulfanyl)apoaranotin was isolated from
the fungus Aspergillus terreus BCC 4651. The bioactive peptide
exhibited the growth inhibitory property of Mtb H37Ra with an
MIC value of 1.56 mg/mL [47]. On the other hand,
cordycommunin (a cyclodepsipeptide, C43H69N7O11) was
isolated from the insect pathogenic fungus Ophiocordyceps
communis BCC 16475. The study showed that the
cordycommunin inhibited the growth of Mtb H37Ra with a
signiﬁcant MIC value of 15 mM [48].
In view of the instant demand to develop new peptide derived
drugs as an alternative to existing TB therapy, several fungal
strains have been screened for their antimycobacterial activity.
During 2000–2005, only few fungal metabolites with promising
anti-tubercular properties had been reported. Among those
bioactive metabolites, hirsutellones A–D, isolated from Hirsu-
tella nivea, inhibited the growth of Mtb signiﬁcantly at MIC
values ranging from 0.78 to 3.12 mg/mL [49]. In the line of
searching most active anti-tubercular peptides from fungi, a to-
tal of 82 fungal extracts were screened against Mtb in order to
investigate the potential fungi with antimycobacterial charac-
teristics [50]. Results exhibited that Cylindrocarpon sp. XH9B,
Fusarium sp. TA54, Fusarium XH1Ga, Gliocladium
penicillioides TH04 and TH21, Gliocladium sp. TH16,
Kutilakesa sp. MR46, and Verticillium sp. TH28 had
signiﬁcant anti-tubercular activity with MIC values ranging
from 1.56 to 25 mg/mL.
8. Venom derived anti-tubercular peptides
The disquieting incidence of TB in immunocompromised
people has emphasized the researchers to develop novel antibi-
otics from diverse sources for the growth inhibition of Mtb.
From this point of view, despite the potential anti-tubercular
peptides obtained from prokaryotes and eukaryotes, it is quite
interesting that venoms from reptiles, arthropods etc. had also
been investigated for the treatment of TB. Relatively there are
very few reports on the venoms associated with anti-tubercular
activity to date. In general, snake venoms are complex mix-
tures of bioactive proteins and polypeptides. About 90% of
venom's dry weight constitutes proteinaceous substances [51].
The venomous proteins are of biological concern due to their
distinct and speciﬁc pharmacological and physiological effects,
demonstrating the signiﬁcance of snake venom proteins as
valuable tools for drug development.
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vgf-1 (obtained from Naja atra) against multi-drug resistant
Mtb. The MIC value of this small peptide was found to be
8.5 mg/L using Bactec TB-460 radiometric method. The study
also recommended the in vivo evaluation of vgf-1 in order to
understand the potential role of this peptide against Mtb for the
possible treatment of MDR-TB. In line of this, Bhunia et al. [53]
demonstrated in vitro activities of venoms of Naja naja,
Bungarus fasciatus, Daboia russelli russelli and Naja kaouthia
against MDR-TB strains.
Pandinin 2 (Pin2) is a 24-residue a-helical antimicrobial
peptide characterized from the venom of Pandinus imperator (a
scorpion). It has a central proline residue that forms a structural
“kink” linked to its pore-forming activity towards human RBC.
The “kink” is a structural characteristic of some cationic anti-
microbial peptides that confer them high pore-forming abilities,
for example melittin, alamethicin and pardaxin. The presence of
a proline “kink” in those peptides was correlated to a high
antimicrobial activity. According to the report of Rodriguez
et al. [54], the residue Pro14 of Pin2 was substituted and ﬂanked
using glycine residues (P14G and P14GPG) based on the low
hemolytic activities of antimicrobial peptides with structural
motifs Gly and GlyProGly such as magainin 2 and ponericin
G1 respectively. The short Pin2 variants named Pin2 (14) and
Pin2 (17) showed better growth inhibitory activity at molar
concentrations against Mtb than that of the conventional
antibiotics such as ethambutol, isoniazid and rifampicin.
9. Anti-tubercular peptides from other sources
Furthermore, Microcystins are cyclic heptapeptides that
consists of seven amino acids (ﬁve non-protein and two protein
amino acids). Microcystins are chemically related cyclic pep-
tides and most commonly studied group of cyanotoxins. Ramos
et al. [55] investigated the antimycobacterial activity of
Microcystis aeruginosa extract and microcystin using resazurin
microtiter assay against Mtb. The hexanic extract of
Microcystis aeruginosa (RST 9501 strain) showed activity
against Mtb strains with MIC values between 1.93 mM and
0.06 mM.
Streptomyces from Lienardia totopotens contained a new and
known spirotetronate polyketides called as lobophorins with
varying degrees of bioactivity against Mtb and found that the
lobophorins are relatively potent candidate for TB therapy [56].
Basically, lobophorins belong to a family of bacterial
spirotetronates, In another report, PK34 from bacteriophage
showed Mtb growth inhibitory activity with an MIC value of
50 mg/mL and also exerted strong antimycobacterial activity
in vivo [57]. PK34 could interact to trehalose-6,6-dimycolate
(TDM), which is a major target for antimycobacterial effect.
The receptor afﬁnity and biological characteristics of peptides
are due to their secondary structure. The rational design can
be sufﬁcient to endow antibacterial activity and to circumvent
drawback effects in this potential therapeutic agent [58]. Thus,
understanding the molecular mechanisms and potential of
above mentioned anti-tubercular peptides in response to Mtb
will contribute in the designing and development of new ther-
apeutic drugs. But the there are several factors to consider before
designing a potential drug from anti-tubercular peptides. The
selected peptides have common properties i.e. antimycobacterial
potential but they differ from each other in several physi-
ochemical properties such as sequence length, net charge,amphipathicity, hydrophobicity and solubility. These parameters
will help to induce the antimycobacterial activities and target
speciﬁcity of peptides. In fact, understanding the structure ac-
tivity relationships may contribute in designing a novel anti-
tubercular drug with improved efﬁciency.
10. Current scenario to combat Mtb: where do we
stand now?
In spite of tremendous efforts and monetary substratum by
the sundry institutions of various countries to combat TB, the
disease still remains a leading burden for the world during the
past two decades due to the emerging resistance property of Mtb
against ﬁrst-line drugs, especially isoniazid and rifampicin.
According to WHO [59] report, expert management and frequent
monitoring are required to cure TB. At present, the treatment for
MDR-TB are time consuming that lasts for 18–24 months or
even longer. Additionally, MDR-TB craves the use of second-
line drugs too that are not only expensive but also produces
excruciating side effects. Furthermore, second-line drugs are
much more toxic and exorbitant costlier than the ﬁrst-line
regimen. There is drastic increase in the proportion of drug
resistant Mtb in last few years because of the poor life style,
alcohol abuse, poverty and malnutrition. As a result of poor
treatment outcomes, the disease became a major concern
worldwide, particularly in developing nations. Moreover, at
present moment, India, China, the Russian Federation and South
Africa alone account for nearly 60% of the world's MDR-TB [1]
that represents TB a human danger and public health issue
globally.
According to the latest report of WHO [60], there are
increased total counts for new TB cases globally than in last
few years. In spite of the recent advances and the fact for
curing tuberculosis, the disease remains one of the world's
deadliest threats. The medications for the treatment of TB can
also lead to other serious health issues, such as kidney failure,
liver, or heart disorder, loss of vision or hearing, psychosis
and most importantly HIV infection. Worldwide, 12% of the
9.6 million new TB cases are found to be HIV-positive. In
fact, HIV infection impels the risk of TB infection on exposure,
progression from latent infection to active, and ﬁnally a risk of
mortality if not treated both TB and HIV in time.
At present, the treatment of TB has resurged due to its
expensive therapy, emerging rate of MDR-TB and most
importantly the side effects of currently available drugs world-
wide. One side of the coin shows the increased frequency of Mtb
in HIV infected people that raised a great concern across the
globe. In addition to this, another side of the coin deals with the
several cases worldwide that reported the negative impact of
currently available anti-tubercular drugs on human health. The
regimens and treatment of TB continues to remain a challenging
course with a variety of complications. In fact, the side effects of
the most commonly used anti-tubercular drugs may be mild as
well as fatal. Table 1 enlists the several cases reporting the
complications of presently available anti-tubercular drugs that
might be due to their direct toxicity or immunologic
mechanisms.
The incidence of serious adverse reactions of above
mentioned anti-tubercular drugs during the treatment of TB has
attracted the attention of worldwide researchers to ﬁnd the
effective replacement of existing therapy with null side effects
from other inexpensive sources. The bioactive anti-tubercular
Table 1
Currently available anti-tubercular drugs and their severe complications.
Anti-tubercular drug Severe complications References
Cycloserine Patient developed delirium during the course of treatment for MDR-
TB, showing the association between Cycloserine and delirium.
Patient developed visual hallucinations, disturbed sleep and lack of
ability to recognize the people too.
[61]
Rifampicin Cellular destruction and glomerular endotheliosis which results in
tubular injury and subsequent decrease in renal function.
[62]
Isoniazid and Rifampicin Agranulocytosis and resultant suppression of the cell mediated
immune system, by mechanisms like hypersensitivity or
idiosyncrasy.
[63]
Isoniazid, Rifampicin, Ethambutol and Pyrazinamide Patient developed hepatotoxicity with a sudden onset of serious
ascites at the end of the ﬁrst month of anti-tubercular treatment.
Additionally, the patient had reduction in breath sounds.
[64]
Cycloserine Patient became disoriented, abusive, physically aggressive and
displayed insomnia.
[65]
Rifampicin and Warfarin Patient developed anticoagulation resistance. [66]
Isoniazid and Rifampicin Severe leukopenia. [67]
Pyrazinamide Patient developed persistent vomiting and hepatitis along with severe
gastritis.
[68]
Oral administration of Isoniazid,
Rifampicin, Pyrazinamide and Ethambutol
Patient developed malabsorption. [69]
Isoniazid Patient developed painful bilateral gynecomastia. [70]
Rifampicin, Isoniazid, Ethambutol and Pyrazinamide Patient developed exfoliative dermatitis/erythroderma. [71]
Isoniazid, Rifampacin, Pyrazinamide and Ethambutol Patient developed hepatotoxicity and severe alcohol induced
hepatitis.
[72]
Rifampicin Patient developed thrombocytopenia. [73]
Capreomycin Patient developed optic neuritis i.e. inﬂammation of optic nerve. [74]
Kanamycin, Isoniazid,
Para aminosalicylic acid,
Ethionamide, Cycloserine and Oﬂoxacin
Patient got seizures, developed hearing impairment, and severe
burning sensation in both hands and feet.
[75]
Rifampin, Isoniazid, Pyrazinamide and Ethambutol Pruritic skin eruption and sore throat. Patient developed drug rash
with eosinophilia and systemic symptoms (DRESS) syndrome.
[76]
Ethambutol Patient developed acute blindness with complete bilateral loss of
vision.
[77]
Isoniazid Patient became unnecessarily elated, excessive talker, excessive
speaker. The person became restless, refused food and drugs, and
showed insomnia. The patient also developed auditory hallucination
and impaired judgment.
[78]
Pyrazinamide Patient developed mild pruritus with macular rash covering her face
and arms on exposure to sunlight. Later, it became severe and
developed into blistering.
[79]
Rifampicin and Isoniazid Development of consciousness disturbance with ﬂapping tremor and
high ammonia level, and diagnosed with fulminant hepatic failure.
[80]
Isoniazid Patient developed pancreatitis. [81]
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combat Mtb. Such an effective approach may avoid not only the
existing problems of side effects associated with high-dose
therapy of TB but also exemplify its superiority to the currently
available expensive treatment.
11. Clinical trials status of currently available anti-
tubercular drugs
In last few decades, several anti-tubercular agents have been
examined for their effectiveness towards drug-susceptible and
drug resistant TB. Few of the drugs developed from those anti-
tubercular agents after advanced screening process are scheduled
for clinical trials in 2016. At present, very few anti-tubercular
agents are in pre-clinical and clinical development. In fact, the
major purpose of these clinical studies is to assess the non-
toxicity and efﬁcacy of these drugs as standard regimens for
TB treatment.
Ahsan et al. [82] and Palomino and Martin [83] updated an
elaborate report on the drugs currently in clinical trials andalso familiarize few new compounds under pre-clinical devel-
opment. Most of these anti-tubercular drugs under different
phases of clinical trials show antimycobacterial property against
Mtb by inhibiting bacterial cell wall as well as protein synthesis.
Rifapentine and TMC207 are DNA dependent RNA polymerase
and ATPase synthesis inhibitor respectively. PBTZ 169 binds
with decaprenylphosphoryl-beta-D-ribose 2-epimerase and in-
hibits the growth of Mtb. TBI-166 targets bacterial membrane
and ion transport system. SQ-641 inhibits Translocase-1. On the
other hand CPZEN-45, DC-159a and Q-203 targets WecA, GyrA
activity and cytochrome bc1 complex of Mtb respectively [83].
In last four decades, among the clinically trialled drugs, only
TMC207 (now commercialized as bedaquiline) has received
FDA approval for the treatment of MDR-TB after Phase II trials.
Due to the failure of most of the drugs for TB therapy in clinical
trial studies and severe complications of currently available anti-
tubercular drugs to the patients, it is the right time to undertake a
critical step in discovering novel anti-tubercular drugs/agents
from most suitable sources. Keeping in view of the previous
ﬁndings, anti-tubercular peptides have created a new prospect to
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acterized anti-tubercular peptides from various sources may be
utilized in lieu of the existing drugs by dint of their novel mode
of action that may contribute to combat MDR-TB. However, the
non-toxicity properties of the anti-tubercular peptides to the
patients, superiority to currently available drugs and preliminary
efﬁcacy outcome would be crucial factors during different
phases of clinical trial studies.
TB-Platform for Aggregation of Clinical TB Studies (TB-
PACTS) is the newly launched data-sharing stage for TB clinical
trial studies that makes these data publicly available. It is a new
tool that provides a larger sample size, an opportunity to analyze
speciﬁc populations, and to ﬁnd commonalities that were not
picked up in the single trials. This tool is valuable in the ﬁght
against TB. In fact, TB-PACTS collaborate with Critical Path
Institute (C-Path) as well as St. George's University of London.
12. Anti-tubercular peptides for the treatment of TB:
why do we need this?
New anti-tubercular drugs of distinct origin are desperately
required not only due to the complexity and severe side effects
of the current TB drug regimes but also because of the emerging
worriment of MDR- or XDR-TB. In last few years, an urgent
obligation for the discovery of new TB drugs has heightened due
to the negative interaction between anti-tubercular drugs and
anti-retroviral drugs administrated to HIV-positive person.
Present-day strategies for TB therapies are time consuming with
adverse concomitant medications due to the development of
drug resistant mycobacterial strains. The lack of novel mode of
anti-tubercular properties of existing drugs is another major
issue for the emergence of drug resistant bacteria. The anti-
tubercular peptides have multiple roles, especially direct
growth inhibition of Mtb and immune-modulation activity dur-
ing the bacterial infection. The lengthy treatment period,
development of MDR- and XDR-TB strains, severe side effects
from most of the existing antimycobacterial drugs, and chal-
lenges in combating TB patients co-infected with HIV underlie
the indispensable obligation for the implementation of new anti-
tubercular peptides from various provenances. Due to the
conceivable antimycobacterial property, the anti-tubercular
peptides may be exploited substantially to cure TB in a rela-
tively shorter time period and undoubtedly it can be considered
auspicious candidates for the development of efﬁcacious drugs
in future due to their speciﬁc mode of action.
13. Concluding remarks and future perspective
The alarming increase in MDR- or XDR-TB infections are a
deliberate threat to mankind globally that triggered the urgency
to develop novel anti-tubercular agents. Comprehensive litera-
tures on the anti-tubercular properties of peptides from diversi-
form sources have shown an idealistic approach towards the TB
cure. Peptides associated with human immune cells, human non-
immune cells, bacteria, fungi, venoms and other sources have
been demonstrated to be emphatic anti-tubercular agents. These
natural peptides with their unique mechanisms of action are
remarkable arenas for future drug development. An insight into
the correlation between peptide structure and molecular mode of
action will lead to design novel anti-tubercular drugs that might
overcome the complications of existing drugs.Furthermore, novel identiﬁed peptides conjugating to broad
spectrum antibiotics can be another practice towards the
enhancement of mycobactericidal property. Interestingly, anti-
microbial agents at mild concentrations induce total protein
production in microorganisms by regulating transcription
mechanism [84]. Synthesizing novel anti-tubercular proteins or
short peptides in microorganisms under mild stress conditions of
certain antimicrobials can be a dynamic formula to conquer
MDR- or XDR-TB with novel mode of growth inhibitory action.
From 2016, it is a goal to reduce the number of TB deaths by
80–90% in the next thirty to forty years and to ensure the
eradication of TB in a few decades by adapting new strategies
and developing novel drugs, especially from anti-tubercular
peptides in order to escape from the era of multi-drug resistant
Mtb. Further understanding the mode of action, non-toxicity and
immunogenicity of the newly discovered anti-tubercular pep-
tides will act as decisive armours and will guide us to develop
puissant anti-TB drugs in future.
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